According to reports, quiescent AML cells exhibit the highest EZH2 expression, and combining an EZH1/2 dual inhibitor with cytarabine could significantly reduce the number of leukemic granulocyte macrophage progenitors (L-GMPs), with this cell population nearly disappearing (Fujita et al., 2018). The gene discussed is EZH2; the disease is acute myeloid leukemia.